Managing side-effects to the optimum: Valuing a client's experience

Journal of Psychiatric and Mental Health Nursing

Volumn 10, Issue 2, 2003, Pages 147-153

  Sin, J ^a,c   Gamble, C ^b  

^a Berkshire Health Care Foundation Trust   (United Kingdom)

^b OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^c Battle Hospital   (United Kingdom)

Author keywords

Collaborative treatment strategies; Evidence based practice; Medication management; Outcome orientated assessment; Psychopharmacology

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; CLONIDINE; CLOZAPINE; DESMOPRESSIN; DIAZEPAM; FLUOXETINE; IMIPRAMINE; LACTULOSE; LORAZEPAM; NEUROLEPTIC AGENT; SULPIRIDE; VALPROIC ACID;

ADULT; AGRANULOCYTOSIS; AKATHISIA; ALLERGIC REACTION; ANTICHOLINERGIC EFFECT; ARTICLE; AUTONOMIC DYSFUNCTION; CASE REPORT; CONSTIPATION; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; HEART ARREST; HUMAN; HYPERPROLACTINEMIA; HYPERSALIVATION; INCONTINENCE; MALAISE; MALE; MENTAL DISEASE; MENTAL HEALTH CARE; MYOCLONUS; NOCTURIA; NURSE; OBESITY; PARKINSONISM; PATIENT COMPLIANCE; PATIENT MONITORING; PSYCHOPHARMACOLOGY; RELAPSE; RESPIRATORY ARREST; RESTLESSNESS; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SHOCK; SIDE EFFECT; SKIN MANIFESTATION; TARDIVE DYSKINESIA; URINARY DYSFUNCTION; URINE INCONTINENCE; VERTIGO; WEIGHT GAIN; ADOLESCENT; METHODOLOGY; NURSING; NURSING ASSESSMENT; TOXICITY AND INTOXICATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; HUMANS; MALE; NEUROTOXICITY SYNDROMES; NURSING ASSESSMENT; PATIENT COMPLIANCE; SCHIZOPHRENIA;

EID: 0037983049     PISSN: 13510126     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2850.2003.00564.x     Document Type: Article

References (35)

1. Baguley I. & Baguley C. (1999) Psychosocial interventions in the treatment of psychosis. Mental Health Care 21, 334-337.
2. Bebbington P.E., Wilkins S., Jones P. et al. (1993) Life event and psychosis. Initial results from the Camberwell collaborative psychosis study. British Journal of Psychiatry 162, 72-79.
3. Bennett J., Done J., Harrison-Read P. & Hunt B. (1995a) A rating scale/checklist for the assessment of the side-effects of antipsychotic drugs. In: Community Psychiatric Nursing: a Research Perspective, Vol. 3 (eds Brooker, C. & White, E.), pp. 1-19. Chapman & Hall, London.
4. Bennett J., Done J. & Hunt B. (1995b) Assessing the side-effects of antipsychotic drugs: a survey of CPN practice. Journal of Psychiatric and Mental Health Nursing 2, 177-182.
5. Birchwood M. & Tarrier N. (1992) Innovations in the Psychological Management of Schizophrenia: Assessment, Treatment and Services. Wiley, Chichester.
6. Buchanan R.W. (1995) Clozapine: efficacy and safety. Schizophrenia Bulletin 21, 579-593.
7. Burnett S. (1994) A new lease on life. Nursing Times 90 (30), 57.
8. Clozapine Study Group (1993) The safety and efficacy of clozapine in severe treatment-resistant schizophrenic clients in the U.K. British Journal of Psychiatry 163, 150-154.
9. Clozaril-Novartis (1999) Summary of Product Characteristics -UK Specific. Novartis, Surrey.
10. Corrigan P.W., Liberman R.P. & Engel J.D. (1990) From non-compliance to collaboration in the treatment of schizophrenia. Hospital Community Psychiatry 41, 1203-1211.
11. Day J.C., Wood G., Dewey M. & Bentall R.P. (1995) A self-rating scale for measuring neuroleptic side-effects. British Journal of Psychiatry 166, 650-653.
12. Dev V.J. & Krupp P. (1995) Adverse event profile and safety of clozapine. Review of Contemporary Pharmacotherapy 6, 197 208.
13. Finn S.E., Bailey J.M., Schultz R.T. & Faber R. (1990) Subjective utility ratings of neuroleptics in treating schizophrenia. Psychological Medicine 20, 843-848.
14. Fowler D., Garety P. & Kuipers E. (1995) Cognitive Behavioural Therapy for Psychosis. Wiley, Chichester.
15. Gardner B., Owen L. & Thompson S. (1999) Compliance: the need for a fresh approach. Mental Health Nursing 19, 18-22.
16. Gray R. (1999) Medication Management Handout Pack. Institute of Psychiatry, London.
17. Howard A. & Reveley A. (2000) Review of compliance in schizophrenia. Schizophrenia Monitor 10, 1-3.
18. Kane J.M. (1992) Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. British Journal of Psychiatry 160 (Suppl. 17), 41-45.
19. Kane J., Honigfeld G., Singer J. et al. (1988) Clozapine for the treatment-resistant schizophrenic (a double-blind comparison with chlorpromazine). Archives of General Psychiatry 45, 789-796.
20. Kemp R., Hayward P., Applewhaite G., Everitt B. & David A. (1996) Compliance therapy in psychotic clients: randomised controlled trial. British Medical Journal 312, 345-349.
21. King D., ed. (1995) Seminars in Clinical Psychopharmacology. Royal College of Psychiatrists, London.
22. Krawiecka M., Goldberg D. & Vaughn M. (1977) A standardised psychiatric assessment scale for rating chronic psychotic clients. Acta Psychiatrica Scandinavica 55, 299-308.
23. Lieberman J.A. & Safferman A.Z. (1992) Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatry Quarterly 62, 51-70.
24. Lieberman J.A., Safferman A.Z., Pollack S. et al. (1994) Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. American Journal of Psychiatry 151, 1744-1752.
25. Lindstrom L.H. (1988) The effect of long-term treatment with clozapine in schizophrenia: a retrospective study in 96 clients treated with clozapine for up to 13 years. Acta Psychiatrica Scandinavica Supplementum 77, 524-529.
26. Marland G. (1998) Partnerships encourage clients to comply with treatment. Nursing Times 94, 58-59.
27. Marland G. & Sharkey V. (1999) Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of literature. Journal of Advanced Nursing 30, 1255-1262.
28. Meltzer H.Y. (1992) The importance of serotonin-dopamine interactions in the action of clozapine. British Journal of Psychiatry 160 (Suppl. 17), 22-29.
29. Meltzer H.Y. (1995) Clozapine: is another view valid? American Journal of Psychiatry 152, 821-825.
30. Meltzer H.Y., Burnett D., Bastani B. et al. (1990) Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic clients. Hospital Community Psychiatry 41, 892-897.
31. National Schizophrenia Fellowship (1996) National Schizophrenia Fellowship Fact Sheet 1, 3rd edn. NSF, London.
32. Shiloh R., Zemishlany Z., Aizenberg M. et al. (1997) Sulpiride augmentation in people with schizophrenia partially responsive to clozapine (a double-blind, placebo-controlled study). British Journal of Psychiatry 171, 569-573.
33. Sin J. (2000) One step at a time: negative symptoms. Mental Health Care 4, 97-101.
34. Sullivan G., Wells K.B. & Leake B. (1992) Clinical factors associated with better quality of life in a seriously mentally ill population. Hospital and Community Psychiatry 43, 794-799.
35. Taylor D. & Hardy S. (1997) Psychopharmacology. In: Stuart and Sundeen's Mental Health Nursing Principles and Practice (eds Thomas, B., Hardy, S. & Cutting, P.). Mosby, St Louis.